showed that RAPA administration inhibited host C W + and CD8+ T-cell expansion that leads to graft rejection. To further investigate the effect of RAPA on T-cell subpopulations, we used two congenic donor mouse stains with isolated MHC class I (bml) or class II (bm12) mutations. In these studies, we showed that RAPA administration can inhibit MHC class l-restricted CD8+ or class Il-restricted CD4+ T-cell-mediated graft rejection without compromising recipient survival. The RAPA-facilitated alloengraftment is multilineage and durable. We have also shown that RAPA speeds hematopoietic recovery post-BMT. We conclude that RAPA represents a new therapeutic modality for promoting alloengraftment and accelerating hematopoietic recovery. rejection of T-cell-depleted (TCD) marrow grafts. In fact, RAPA is known to inhibit the generation of precursor cytotoxic T lymphocytes (pCTL) and, to a lesser extent, CTL generation,26 which have been implicated in the host-mediated rejection of TCD allogeneic BM.27 Recently, we have shown that RAPA is a potent immunosuppressive agent in murine BMT, with documented efficacy in the treatment of ongoing GVHD" and as an agent for GVHD prevention2' in a murine model of lethal GVHD induced across the major histocompatibility complex (MHC) bamer. In the latter study, RAPA (1.5 mg/kg/dose on days 0 through 13 and thrice weekly through day 29 post-BMT) administered to irradiated B1O.BR (H-2k) recipients of fully allogeneic C57BL/6 (H-2b) donor BM and splenocytes allowed 80% of mice (n = 30) to survive the entire 100-day observation period without GVHD, in contrast to 0% of the vehicle controls (n = 20).
We were particularly interested in comparing the effect of RAPA to pan-TCD, which is also a highly successful means of preventing GVHD, because the latter strategy compromises all~engraftment.~~ In this report, we will present data that show that RAPA prevents graft rejection in mice that receive fully allogeneic donor grafts. In addition, we provide evidence that RAPA can inhibit graft rejection mediated by CD8+ or CD4+ cells that recognize an isolated MHC class I (H-2bml) or MHC class I1 (H-2bm'2) only disparity caused by a limited number"3 of amino acid mutations in the MHC
MATERIALS AND METHODS
Mice. C57BL/6 (H-2b, Ly5.1+), C57BL/6-Ly5.2 (H-2b, Ly5.2+), and BALB/c (H-2d) donor mice and recipient mice were purchased from the National Institutes of Health (Bethesda, MD). B6.C-H-RAPAMYCIN PROMOTES BONE MARROW ENGRAFTMENT 60 1 l".
Our transplant protocol for engraftment has been described in Total body irradiation (TBI) dosages were chosen for conditioning based on previous studies in which anti-Thy 1.2 +C treatment of BM gave minimal donor cell engraftment. TB1 doses were 6.5 Gy/mouse (unless otherwise indicated) for C57BL/6 recipients of BALB/c or DBA/I donor BM.% Recently, we have also established a murine system of graft rejection of isolated MHC disparities using B6.C-H-2b"' mice and B6.C-H-2bm'2 donor BM transplanted into C57BL/6-Ly 5.2 recipients receiving 5.5 C y TBI.)' In all cases, TB1 was administered from a Philips RT 250 Orthovoltage Therapy Unit (Philips Medical Systems, Brookfield, WI) filtered through 0.35 mm Cu at a final absorbed dose rate of 0.41 Gy/min at 225 kV and 17 mA.
Ex vivo TCD of I8 X IO6 BALB/c BM cells/recipient (unless othenvise indicated) or 10 X lo6 DBA/I BM cells/recipient was performed using anti-Thy l .2 monoclonal antibody (MoAb) (hybridoma 30-H12, rat IgG2b; from American Tissue Type Culture Collection, Rockville, MD) plus complement as previously described?6"* For B6.C-H-2bm' mice and B6.C-H-2b""2 transplants, recipients received 2.5 X IO6 donor TCD BM cells. After treatment, all aliquots were washed, resuspended, and adjusted for caudal vein injection. Cell doses were established in prior studies.",35
Long-term engraftment as measured by flow cytometry. Chimerism of peripheral blood cells was analyzed in all experiments at 7 to 8 weeks post-BMT. Peripheral blood was prepared for fluorescenceactivated cell sorter (FACS) analysis by density gradient centrifugation using Isolymph (Gallard-Schlesinger, Carle Place, NY) to remove red blood cells. Engraftment was quantitated by analyzing the cell surface binding ofanti-H-2 MoAb linked to fluorochrome. For quantification of BALB/c or DBA/ 1 donor cell engraftment, anti-H-2d (hybridoma 34-5-88, mouse IgG2a)39 or anti-H-2q (hybridoma 66-3.5, mouse IgG; both provided by Dr David Sachs, National Institutes of Health)@ was directly conjugated to fluorescein isothiocyanate (FITC). For host cell quantification, anti-H-2b (hybridoma EH144, mouse IgG; provided by Dr T.V. Rajan, University of Connecticut, CT) was directly conjugated to phycoerythrin (PE). For B6.C-H-2bm' or B6.C-H-2h'2 transplants, because donors expressed Ly5. I and recipients expressed Ly5.2, mice were typed with rat MoAb IgG2a aLy 5.2 from clone A20-1.7 (host) and rat MoAb IgG2a aLy 5.1 from clone 104-2 (donor) (both provided by Dr U. Hammerling New York, W ) .
Anti-Ly 5.2 was FITC-labeled and aLy 5.1 was PE-labeled for the two-color experiments. Labelings were performed as previously de~ribed.~'
In some experiments, peripheral blood or splenic T-cell populations were examined at various periods of time post-BMT (as indicated) for donor or host origin. In those experiments, three-color FACS analysis was performed as previously described incorporating donor-and host-specific fluorochrome labeled MoAb and a T-cell or B-cell lineage marker as a third fluorochrome-labeled MoAb. Anti-CD3s anti-CD4, anti-CDS, B-cell (B220), and granulocyte (gran-l) MoAbs were in combination with each other and/or with donor-or host-specific fluorochrome-labeled MoAb. These reagents were purchased from PharMingen (San Diego, CA) as direct FITC or PE conjugates. For three-color studies, the third color was indirectly measured by adding streptavidin-labeled Red 6 13 (SARed 613; GIBCO Laboratories, Grand Island, NY) for an additional 1 hour at 4°C.
In all experiments, peripheral blood mononuclear and granulocyte cells or splenocytes were incubated with 2.462 to block Fc receptor~~' and then incubated with an optimal concentration of fluorochrome-labeled MoAb for 45 minutes at PC. Cells were washed three times and resuspended for analysis. An antihuman CD7 (hybridoma 3A I E, mouse IgG; provided by D r Barton Haynes, Duke University, Durham, NCr" was conjugated to FITC, PE, or biotin (along with SA Red 6 13) to determine control (background) staining. Background values were subtracted from values obtained with relevant MoAbs as previously described!' All results were obtained using a FACScan (J3ecton Dickinson, Mountain View, CA). Forward and side scatter settings were gated to exclude red blood cells and debris. In one experiment, peripheral blood cell populations were further analyzed for the proportion of engraftment of lymphocytes, monocytes, and granulocytes by gating on cell populations with appropriate forward and side scatter settings for this purpose. Seven thousand cells were analyzed for each determination.
RAPA administration. A stock solution of 2.5 mg/mL RAPA in carboxymethylcellulose (CMC; Sigma C50 13, lot 109F036 I ; Sigma, St Louis, MO) was prepared. RAPA was resuspended in CMC at a final concentration of 0.2% CMC for injections and administered at a dose of 1.5 mg/kg/dose intraperitoneally (IP) begm ning on the day of BMT and continued daily through day 13 post-BMT. CMC alone was administered as a control.
I n vivo depletion of CD4-or CD8-expressing cells with MoAbs. For experiments involving B6.C-H-2bm' mice and B6.C-H-2bm'2 donor cells transplanted into C57BL/6-Ly5.2 recipients, in vivo depletions of CD4 or CD8 cell populations were performed to document that the graft rejection process in these strain combinations was caused by CD4+ or CD8+ cells, respectively, as previously described for these donor-recipient strain combination^. ' ages (from 49% to 6%). The actuarial survival rate at 3 months post-BMT was not significantly different in the controls (60%) versus the RAPA-treated recipients (70%).
To determine if RAPA could inhibit graft rejection in a murine BMT system in which host T cells and host NK cells cause the rejection of TCD fully allogeneic BM, we substituted BALB/c for DBA/l donors.47 Only the former mice express hematopoietic histocompatibility (Hh l) antigens that are the targets of NK-mediated graft rejection.48 As shown in Table 1 , RAPA administration abolished the graft rejection process, as evidenced by the significant (P 5 .OO 1) increase in mean donor cells percentages (from 13% to 92%) and decrease in mean host cell percentages (from 78% to 5%). The actuarial survival rate at 3 months post-BMT was 50% in controls and 90% in RAPA-treated recipients. Thus, RAPA administration was capable of inhibiting graft rejection in two murine systems in which host T cells, with or without a contribution from host NK cells, mediated the graft rejection process and did not compromise recipient survival.
Because RAPA administration has not, to our knowledge, been previously reported in murine BMT recipients, we monitored the hematopoietic recovery of RAPA-injected recipients. As shown in Table 2 , recipients of RAPA and BLAZAR ET AL TCD DBA/1 or BALB/c donor BM had significant increases in multilineage reconstitution, including cells of the myeloid, lymphoid, and erythroid lineages on day 14, which persisted throughout the 28-day observation period.
RAPA administration,facilitutes the engrujiment qf TCD BALB/c donor BM transplanted into irradiuted recipients under corzditions in which BM cell dose and TBI dose strongly,fuvorgra/i rejection. To determine the potency of the RAPA-induced promotion of alloengraftment, we performed additional experiments in which BM ceIl dose and TB1 were reduced. As shown in Table 3 , reduction of the dose of TCD BALB/c donor BM to as few as 5 X lo6 cells resulted in a mean donor percentage of 0% and a mean host percentage of 100%. RAPA administration prevented the graft rejection process. Recipients of RAPA injections had a mean donor percentage of 95% and a mean host percentage of 5%. Reduction of the TB1 dose from 6 5 0 cGy to 600 cGy also reduced the engraftment rates with mean donor percentages S 17% and mean host percentages 284% in recipients of 5 to 18 X 1 O6 TCD BALB/c BM cells. Recipients of RAPA injections had significantly (P I .OOl) higher engraftment rates, with a mean donor percentage of%% and a mean host percentage of S%. Further analysis of the RAPAtreated mice showed that the lymphocyte, monocyte, and granulocyte populations in recipients conditioned with either 6.5 or 6.0 Gy TB1 in each mouse were each almost exclusively of donor origin, correlating closely with results obtained in peripheral blood cells. RAPA-treated recipients of 5 X IO6 TCD BALB/c BM had equivalent (BALB/c recipients of 18 X lo6 TCD + 6.5 Gy TBI) or significantly (all other groups) higher percentages of lymphocytes as compared with non-RAPA-treated groups, indicating that RAPA treatment did not adversely affect peripheral blood lymphoid repopulation despite its known inhibitory effect on lymphocyte function. These data indicate that RAPA reproducibly facilitates the engraftment of TCD BALB/c donor BM under conditions that are rate-limiting for alloengraftment in the absence of RAPA. Moreover, RAPA administration permits the engraftment of multiple cell lineages even under these rigorous graft rejecting conditions.
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f ? e Table 5 , RAPA administration leads to significant (P < RAPA administration resulted in a prolonged inhibition of Table 5 to determine if T-cell reconstitution. 
C57BL/6 recipients were irradiated on day -1 and received transplants of TCD BALB/c BM cells on day 0 as described in the Materials and Methods.
Post-BMT, mice were injected with CMC (vehicle control) or RAPA (1.5 mg/kg/dose days Othrough 13) as described in the Materials and Methods. On H-Zb H-Zb P < .05 as compared with CMC-injected recipients. t P < . l and P z .05 as compared with CMC-injected recipients.
peripheral blood closely paralleled the T-cell results. These data provide additional information as to the effect of RAPA on facilitating the engraftment of progenitor cells with multilineage properties.
To determine the durability of RAPA facilitated alloengraftment, we electively killed murine recipients of H-2bm'2 TCD BM grafts on day 130 post-BMT to obtain splenocytes for a comprehensive analysis of lymphoid cell subpopulations. These data (Table 7) show that splenic B cells and T cells, and, by subtraction of values obtained from the whole splenocyte population, nonlymphoid lineage cells, are each almost exclusively of donor origin. Analysis of thymocytes from these representative mice showed 0% mean donor cell percentages in the PBS-treated group and 99% mean donor cell percentages in the RAPA-treated group. Thymocyte number was higher in the RAPA-treated group as compared with the PBS-treated group (mean numbers, 75 X lo6 v 64 X lo6, respectively), providing evidence that RAPA treatment does not permanently impair thymus repopulation after irradiation and BM rescue (data not shown). Thus, the donor graft in RAPA-treated recipients is long-lived.
Actuarial survival rates at 3 months post-BMT in recipi- B6.C-H-2h'' C57BL/6-Ly5.2 Anti-CD8 MoAb 1 0 + 4 9 0 + 4 Anti-Thyl.2 + C-treated BM (2.5 x 1 Os) was infused on day 0 into recipients that irradiated with 550 cGy TB1 by X-ray on day -1. Ten mice per group received transplants. On day -1 pre-BMT and continuing weekly for 4 weeks post-BMT, mice were injected with 400 pg/dose purified anti-CD4 or anti-CD8 or RAPA (1.5 mg/kg/dose for days 0 through 13). Peripheral blood cells were obtained 7 to 8 weeks post-BMT for chimerism as described in the Materials and Methods. Values are mean percentages +l standard error of the mean as determined by two-color FACS using donor-and hostspecific fluorochrome-labeled MoAbs.
* P S .001 as compared with PBS control. t P S .006 as compared with the anti-CD8 MoAb group (bml experiment) or the anti-CD4 MoAb group (bml2 experiment). 
Granulocytes
In Vivo Host ents of MHC class I only disparate grafts was 90% to 100% in all groups. Actuarial survival rates at 3 months post-BMT in recipients of MHC class I1 only disparate grafts was 90% in all groups except the CD8-depleted group, which had a 70% actuarial survival rate. Thus, RAPA administration was capable of reversing graft rejection caused either by CD4+ or CD8+ T-cell subpopulations but did not lead to a persistent state of T-cell (or B-cell) lymphopenia. Consistent with these effects of RAPA on alloengraftment, multilineage hematopoietic recovery on day 14 post-BMT (Table 8) in both systems was superior in RAPAtreated mice compared with control BMT recipients. Hematopoietic recovery in RAPA-treated mice was also superior to those mice that received selective T-cell depletion in vivo that was not associated with graft promotion (ie, CD8' or CD4+ T-cell depletion for recipients of MHC class I1 or class I only disparate TCD donor BM grafts, respectively). In comparison to groups of mice treated with MoAbs to ensure depletion ofthe appropriate T-cell subpopulation, mice treated with RAPA had higher (bm l) or similar (bm 12) absolute neutrophil counts and hematocrit values but lower absolute numbers of lymphocytes. The hematopoietic effects in general (with the exception of the higher hematocrit values) normalized by day 28 post-BMT.
DISCUSSION
We have observed that RAPA administration prevents host T-cell-mediated rejection of TCD allogeneic donor grafts, regardless of the type of T cell (CD4' or CD8+) that mediates the graft rejection. Presumably, the fact that RAPA administration can inhibit both types of T cells accounts for the highly effective inhibition of GVHD in lethally irradiated recipients of fully allogeneic donor graft^.*'',^^ There are at least 4 possible explanations for the RAPA induced inhibition of graft rejection in these systems. ( l ) RAPA directly interferes with cytokine responsiveness in both CD4+ and CD8+ T cells, thereby precluding the expansion of host antidonor CD4' or CD8+ CTL populations.
Host antidonor CTLs could be present but at a frequency insufficient to mediate graft rejection. (2) RAPA induces antigen-specific nonresponsiveness in host T cells that specifically prevents recognition of donor TCD BM. Host antidonor CTLs would not develop from the precursor cells and these cells would be specifically nonresponsive to donor alloantigen. (3) RAPA is directly toxic to CD4+ and CD8' T cells. (4) RAPA induces a counterregulatory cell population (eg, donor veto cells or host suppressor cells).
We favor either the first or second explanation to account for the global nature of RAPA on inhibiting T-cell-mediated graft rejection. Regarding the first mechanism, RAPA has a well-defined effect on inhibiting lymphokine response8"' (rather than lymphokine production). Cyclosporin A (which does inhibit lymphokine production) and RAPA each act on a different limb of the cytokine:cytokine receptor signalling system and bind to a different set of in- (1) 21 (4) l ( 0 ) 13(3) O(0) 7(2) O(0) 32 (11) B6.C-H-2"" C57BL/6-Ly5.2 RAPA 1.5 mg/kg/dose 61 (7) 4 (1) 19 (2) 3 (1) 12 (1) 1 (0) RAPA inhibits pCTL and to a lesser extent CTL generationZ6 most likely caused by the effect of RAPA on inhibiting the response of T cells to cytokines such as IL-2 that are facilitory for T-cell expansion. Host antidonor CTLs have been isolated from irradiated C57BL/6 recipients of TCD BALB/c donor BM grafts and shown to be capable of causing graft rejection in a specific fashion when adoptively transferred to secondary recipient^.^' Because recipients would not have been previously exposed to donor alloantigens, CTLs with antidonor reactivity would most likely need to be expanded (and hence depend on IL-2 responsiveness) to complete the rejection process. The time frame involved with such an expansion would correspond to our previous studies in the BALB/c TCD BM model system in which graft rejection appears to occur between days 7 and 1 l post-BMT. FACS analysis presented in this study (Table 4) is also consistent with the requirements for CTL expansion.
Regarding the second mechanism, it is possible that the failure of host T cells to mediate graft rejection is caused by an inhibition in their capability of specifically expanding in response to donor alloantigen. These cells would lose their capability of mounting a response to the original alloantigen(s) present in sufficient concentration (to trigger the Tcell receptor) during RAPA administration. This process, known as is a state of antigen (peptide)-specific nonresponsiveness such that cells are not capable of responding to rechallenge with the antigen (or peptide) present during the generation of the anergic state. IL-2 present during the anergy induction process will prevent anergy.53 Anergy has been induced in antigen-specific T-cell clones in vitro and has been shown to be an important mechanism for peripheral tolerance induction in vivo in T cells that encounter antigen present in the periphery but not in the thyand in T cells that encounter antigen presented by non-BM-derived antigen-presenting cells that lack the necessary costimulatory molecules for stimulating an effective T-cell r e~p o n s e .~~-~~ In the latter instance, these costimulatory molecules function to stabilize IL-2 m e s~a g e '~>~~.~* so that sufficient IL-2 is produced to trigger T-cell division. Although the mechanism for anergy induction is not known, one hypothesis suggests that anergy occurs as a consequence of putative anergy inducing proteins that can accumulate in cells that have their T-cell receptor signalled by MHC molecules and foreign antigens (or peptides) but are not capable of undergoing cell di~ision.'~ Cell division, as would occur in the presence of 1L-2 (but not in the presence of RAPA), would dilute these putative anergy proteins such that antigen-specific responsiveness would be maintained.
Thus, RAPA, which inhibits IL-2 responsiveness in T cells, could render host CTLs and their precursors anergic to donor alloantigen. In engraftment terms, host T cells with antidonor specificities but not other specificities (such as antiviral or antileukemia) would fail to expand early post-BMT because the donor alloantigen would be present in sufficient concentrations to typically generate a host T-cell response. In the later post-BMT period, when RAPA is discontinued, T cells that have not been exposed to RAPA could, at least theoretically, mediate antiviral or antileukemia effects at the time of antigenic load such as during a recent viral infection or at a time when leukemia cells are proliferating. RAPA may facilitate the anergy induction process by preventing the host T cell from responding to IL-2 produced by itself or other T cells after their encounter with alloantigen and in the presence ofcostimulation.
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Regarding the third mechanism, it is possible but highly unlikely that RAPA is directly toxic to T cells. Whereas early reports suggested that RAPA may be an effective antineoplastic agent against T-cell and B-cell malignancies, more recent studies have shown that RAPA does not kill T cells in vitro and does not result in peripheral lymphopenia in vivo.6o However, in the studies of Zheng et a1,6' the thymic architecture was severely disrupted during RAPA administration despite the absence of preceding thymic irradiation, showing that RAPA alone will induce thymic dysplasia. These investigators also showed that RAPA administered in nonirradiated mice induced a significant (50% to 80%) and prolonged reduction of CD4+CD8+ thymocytesbl that could alter peripheral T-cell reconstitution after BMT. Because of the timing of the graft rejection process, it is unlikely that the effects of RAPA on thymic maturation and emigration of T cells from the thymus to the periphery would account for the inhibition of graft rejection. In fact, the newly educated peripheral T cells would be nonresponsive to host alloantigens. Thus, we do not favor this explanation for our results. Moreover, long-term (2 months post-BMT) chimeras had normal numbers of mature donor CD4+ or CD8+ T-cell populations in the periphery (Tables  6 and 7 ) and in the central area (data not shown).
Regarding the fourth mechanism, we were not able to show that RAPA-treated recipients of TCD BM allografts had increased numbers of negative regulatory cells such as CD3+CD4-CD8-cells, which have been implicated in GVHD prote~tion,6'~~ although other regulatory cells could be involved. Although we cannot exclude this possibility, we also have no direct evidence to support this hypothesis as the mechanism of RAPA action on prevention of graft rejection.
Distinguishing the first (failure of expansion of host antidonor graft rejection cells) from the second mechanism (anergy) will be problematic because, as shown in Table 3 , there are few ( < O S X 1 Ob) host T cells in RAPA-treated mice during the critical period of graft rejection. Moreover, irradiated host T cells in the early post-BMT period are likely to be poor responders in vitro to donor alloantigens, especially if treated with RAPA because RAPA (which is highly lipophilic) would inhibit in vitro IL-2 responsiveness necessary for analysis of the specificity of T-cell function. Functional analysis of donor cells in long-term chimeras have consistently shown a lack of antihost responsiveness, whereas mice that have rejected their grafts have intact antidonor responsiveness.
To our knowledge, the in vivo effects of RAPA on hematopoiesis have not previously been studied in irradiated BMT recipients. Therefore, we performed detailed examinations of the peripheral hematopoietic reconstitution of RAPA-treated mice. In all 4 engraftment systems, we observed that RAPA administration accelerated multilineage (myeloid, lymphoid, and erythroid) reconstitution, perhaps as a result of its effects on preventing the slower recovery associated with graft rejection in these donor-recipient strain combinations. In addition, RAPA appears to have an effect on the erythroid lineage independent ofthe leukocytes because hematocrit values in RAPA-treated mice exceeded those in groups of mice that had high levels of engraftment (such as anti-CD8 or anti-CD4 MoAb-treated recipients of MHC class I or class I1 only disparate TCD BM) as well as in normal control mice whose hematocrit values never reach 50%. The erythroid effects of RAPA are currently under investigation.
In summary, we have shown that RAPA administration is a potent inhibitor of host CD4+ and host CD8+ T-cellmediated rejection of TCD allogeneic BM without adversely affecting hematopoietic recovery or survival. RAPA administration provided durable, multilineage engraftment of allogeneic TCD BM under conditions that favored graft rejection. Because RAPA is also a highly effective means of inhibiting GVHD'' and in treating ongoing GVHD," further consideration is warranted for human BMT trials as a single agent or in combination with cyclosporin A,5OX5I which is a mainstay6' of current GVHD prophylactic regimens.
